Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Intensity Modulated Radiation Therapy - Gyne Cancer

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II, Phase I Treatment Active 18 and over Other UHN REB 03-0298-C
NCT00188578

Trial Description

Summary

Standard treatment for gynecological cancer is radiation therapy in two phases; whole pelvic radiation and then an internal radiation boost, also called a brachytherapy boost, to treat any remaining tumour.

The purpose of this study is to test an alternative radiation boost treatment called conformal intensity modulated radiation therapy or IMRT. Currently, we do not have complete information on the overall effectiveness of IMRT compared to brachytherapy or conformal radiotherapy. We know that IMRT allows the radiation beams to be more accurately focused on the tumor, thereby sparing more normal tissue from radiation damage and lowering risks of side effects. We are investigating the extent to which IMRT can be used to protect normal tissues in patients with cervix, uterine or vaginal cancer from the radiation beams and how much the side effects of radiation are reduced.

Eligibility Criteria

Inclusion Criteria:

Patients with gynecological tumours who have received whole pelvic radiotherapy but who are not suitable for intracavitary brachytherapy

informed consent

Trial Contact Information

Trial Lead Organizations/Sponsors

Toronto Western Hospital

Princess Margaret Hospital

Anthony Fyles, MD

Principal Investigator

Anthony Fyles, MD		Ph: 416-946-6522
		Email: anthony.fyles@rmp.uhn.on.ca

Trial Sites

Canada

Ontario

Toronto

Princess Margaret Hospital

Anthony Fyles, MD Ph: 416-946-6522

Email: anthony.fyles@rmp.uhn.on.ca

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00188578
Information obtained from ClinicalTrials.gov on March 18, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.